The NEJM say "The efficacy...is unclear" but reading down the page a bit with my foggy brain, it doesn't look like they were.
Both, it is a 51% relative decrease an a 2.9% absolute decrease in Covid-19–related hospitalization or ER visits with >6hours observation in those who received inf-lambda. Both numbers are important to consider, but studies and press releases will often only give the relative, it usually sounds more impressive.Is 5.6% vs 2.7% really a 51% increase, or just a 2.9% increase?
Among the 2,085 patients who were randomized within 5 days of symptom onset (mITT1 analysis), COVID-19-related hospitalizations and all-cause deaths occurred in 8 of 1,039 patients (0.77%) in the ritonavir-boosted nirmatrelvir arm (paxlovid) and in 66 of 1,046 patients (6.3%) in the placebo arm (89% relative risk reduction; 5.6% estimated absolute reduction; 95% CI, 7.2% to 4.0%; P < 0.001). There were no deaths in the ritonavir-boosted nirmatrelvir arm and 13 deaths in the placebo arm.